Rajiv Bassi

发表

Targeting the platelet-derived growth factor receptor α with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target

Peter Bohlen, Dan Lu, D. Hicklin, 2005, Molecular Cancer Therapeutics.

A Fully Human Recombinant IgG-like Bispecific Antibody to Both the Epidermal Growth Factor Receptor and the Insulin-like Growth Factor Receptor for Enhanced Antitumor Activity*

D. Hicklin, P. Bohlen, Zhen-ping Zhu, 2005, Journal of Biological Chemistry.

A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.

Peter Bohlen, Dan Lu, D. Hicklin, 2003, Cancer research.

Anti–Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune Cells

Zhen-ping Zhu, Yan Wu, D. Ludwig, 2010, Clinical Cancer Research.

Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non–Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor

D. Hicklin, Y. Hadari, J. Tonra, 2007, Clinical Cancer Research.

Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non–small cell lung cancers

D. Hicklin, Sheetal Patel, Y. Hadari, 2007, Molecular Cancer Therapeutics.

Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody.

D. Hicklin, P. Bohlen, Zhen-ping Zhu, 2004, Blood.

Preclinical rationale for combining an EGFR antibody with cisplatin/gemcitabine for the treatment of NSCLC.

Huiling Li, Dhanvanthri S. Deevi, J. Tonra, 2012, Cancer genomics & proteomics.

Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.

Yuan Cheng, D. Hicklin, Zhen-ping Zhu, 2006, Cancer research.

Tumors Established with Cell Lines Selected for Oxaliplatin Resistance Respond to Oxaliplatin if Combined with Cetuximab

L. Ellis, F. Fan, D. Hicklin, 2007, Clinical Cancer Research.

Estimating preclinical efficacy targets utilizing cetuximab efficacy in KRAS mutant and wild-type colorectal cancer models.

K. Paz, Huiling Li, Dhanvanthri S. Deevi, 2011, Anticancer research.

Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.

Lee M Ellis, L. Ellis, D. Hicklin, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Signaling and Inhibits Human Tumor Growth Growth Factor I Receptor Blocks Ligand-Dependent A Fully Human Monoclonal Antibody to the Insulin-Like Updated

D. Hicklin, P. Bohlen, Zhen-ping Zhu, 2003 .

Anti-Vascular Endothelial Growth Factor Receptor-1 Antagonist Antibody as a Therapeutic Agent for Cancer

D. Hicklin, Yan Wu, D. Ludwig, 2006, Clinical Cancer Research.

Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis.

L. Zanetta, F. Liao, D. Hicklin, 2000, Cancer research.

Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice.

D. Hicklin, Zhen-ping Zhu, D. Ludwig, 2005, Cancer research.

Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.

D. Hicklin, D. Patel, X. Kang, 2009, International journal of oncology.

Active Immunization Against the Vascular Endothelial Growth Factor Receptor flk1 Inhibits Tumor Angiogenesis and Metastasis

D. Hicklin, P. Bohlen, A. Hooper, 2002, The Journal of experimental medicine.

An antibody directed against PDGF receptor beta enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody.

Zhen-ping Zhu, Haifan Zhang, D. Ludwig, 2007, Biochemical and biophysical research communications.

Inhibition of Both the Autocrine and the Paracrine Growth of Human Leukemia with a Fully Human Antibody Directed Against Vascular Endothelial Growth Factor Receptor 2

D. Hicklin, P. Bohlen, Zhen-ping Zhu, 2004, Leukemia & lymphoma.

Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.

F. Liao, D. Hicklin, P. Bohlen, 2002, Cancer Research.

Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation.

D. Hicklin, D. Patel, X. Kang, 2009, International journal of oncology.

Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.

Zhen-ping Zhu, Haifan Zhang, D. Ludwig, 2009, Neoplasia.